Loading patent…
AssigneeOpko Ireland Global Holdings, Ltd.
InventorsP. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
Estimating the term…
Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
A pharmaceutical formulation for oral administration comprising (a) a 25-hydroxyvitamin D compound (b) an agent that increases the risk of hypocalcemia, optionally cinacalcet or a salt thereof, and (c) an anticancer agent.
A method of treating hypercalcemia in a patient with parathyroid carcinoma, comprising administering to said patient an effective amount of a 25-hydroxyvitamin D compound by modified release and an effective dose of cinacalcet or a salt thereof in an amount of less than 360 mg daily, wherein said effective amount of cinacalcet or a salt thereof is a reduced dose compared to the effective dose of cinacalcet in the absence of said 25-hydroxyvitamin D administration, and an anticancer agent.
Dependencies are inferred from the claim text.